AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Background: Both atrial fibrillation and venous thromboembolism (VTE) are highly prevalent
among patients with chronic kidney disease (CKD). Until recently, warfarin was the most …

Cardiovascular diseases are highly prevalent among patients on dialysis. For these
diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K …

Background The use of Direct Oral Anticoagulants (DOACs) in patients who have both atrial
fibrillation (AF) and end-stage renal disease (ESRD) requiring hemodialysis remains …

Purpose Patients with atrial fibrillation (AF) and end-stage renal disease on chronic
hemodialysis are at risk for thromboembolic and bleeding events. We aimed to perform a …

Atrial fibrillation (AF) is common in patients with chronic kidney disease (CKD) undergoing
hemodialysis and in this patient population, management in terms of oral anticoagulation …

Background Only small randomized trials have investigated the efficacy and safety of direct
oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in patients with …

Limited pharmacokinetics data are guiding the use of apixaban in end-stage renal disease
(ESRD) patients on hemodialysis but none on peritoneal dialysis. Apixaban could be an …

Atrial fibrillation (AF) is the most common arrhythmia in chronic kidney disease (CKD), with a
close bidirectional relationship between the two entities. The presence of CKD in AF …

A growing variety of cardiac devices are available to monitor or support cardiovascular
function. The entwined nature of cardiovascular disease and kidney disease makes the …